CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will be held Oct. 9-12, 2026, in Phoenix.

Barostim will be featured across eight events at HFSA, including late-breaking clinical data, a rapid-fire session, posters and podium sessions. BENEFIT-HF, the landmark clinical trial initiated earlier this year evaluating Barostim in an expanded population, will also be included in the clinical trial ePoster hub.

New REBALANCE Registry and Real-World HFmrEF Evidence

In a late-breaking session, Dr. Dmitry Yaranov will present new analyses from the REBALANCE Registry, the largest real-world study of Barostim-treated patients to date, evaluating the safety and benefits of Barostim in commercial use.

In a separate rapid-fire session, Dr. Javed Butler will present Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden.

In addition to the REBALANCE and HFmrEF presentations, Barostim will be featured in numerous scientific sessions and activities throughout the HFSA Annual Scientific Meeting 2026.